Search tips
Search criteria 


Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
AAPS PharmSciTech. 2007 October; 8(4): 281–288.
Published online 2007 December 28. doi:  10.1208/pt0804115
PMCID: PMC2750701

Estimation of the percolation thresholds in lobenzarit disodium native dextran matrix tablets


The objective of the present work is to estimate for the first time the percolation threshold of a new series of dextran (native dextran of high molecular weight [B110-1-2, Mw=2×106]), in matrices of lobenzarit disodium (LBD) and to apply the obtained result to the design of hydrophilic matrices for the controlled delivery of this drug. The formulations studied were prepared with different amounts of excipient in the range of 20% to 70% wt/wt. Dissolution studies were performed using the paddle method (100 rpm) and one face water uptake measurements were performed using a modified Enslin apparatus. The Higuchi, zero-order, and Hixson-Crowell models as well as the nonlinear regression model were employed as empiric methods to study the release data. Values of diffusion exponent 0.563<n<0.786 (Korsmeyer equation) for dissolution profile and water uptake mechanism 0.715<n<1 (Davidson and Peppas equation) suggested anomalous or complex mechanisms. On the other hand, the contribution of the relaxation or erosion and of the diffusive mechanism in Peppas-Sahlin equation indicated that the main mechanism for drug delivery from tablets is swelling controlled delivery (Kr/Kd<1). The critical points observed in kinetic parameters above 58.63% vol/vol of native dextran B110-1-2 plus initial porosity in the LBD-dextran matrices with a relative polymer/drug particle size of 4.17 were attributed to the existence of an excipient percolation threshold.

Keywords: Dextran, lobenzarit, percolation, swelling, threshold

Full Text

The Full Text of this article is available as a PDF (378K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Coviello T, Matricardi P, Marianecci C, Alhaique F. Polysaccharide hydrogels for modified release formulations. J Control Release. 2007;119:5–24. doi: 10.1016/j.jconrel.2007.01.004. [PubMed] [Cross Ref]
2. Robyt JF. Dextran. In: Mark HF, Bikales NM, Overberger CG, Menges G, editors. Encyclopedia of Polymer Science and Engineering. New York, NY: John Wiley & Sons; 1986. pp. 752–767.
3. Gil EC, Colarte AI, El Ghzaoui A, Durand D, Delarbre JL, Bataille B. A sugar cane native dextran as an innovative functional excipient for the development of pharmaceutical tablets.Eur J Pharm Biopharm. In press. [PubMed]
4. Ferrero C, Muñoz-Ruiz A, Jiménez-Castellanos MR. Fronts movements as a useful tool for hydrophilic matrix release mechanism elucidation. Int J Pharm. 2000;202:21–28. doi: 10.1016/S0378-5173(00)00407-5. [PubMed] [Cross Ref]
5. Tahara K, Yamamato K, Nishihata T. Overall mechanism behind matrix sustained release (SR) tablets prepared with hydroxypropyl methylcellulose 2910. J Control Release. 1995;35:59–66. doi: 10.1016/0168-3659(95)00021-Y. [Cross Ref]
6. Jamzad S, Tutunji L, Fassihi R. Analysis of macromolecular changes and drug release from hydrophilic matrix systems. Int J Pharm. 2005;292:75–85. doi: 10.1016/j.ijpharm.2004.11.011. [PubMed] [Cross Ref]
7. Gil EC, Colarte AI, Bataille B, Pedráz JL, Heinämäki J. Development and optimization of a novel sustained-release dextran tablet formulation for propranolol hydrochloride. Int J Pharm. 2006;317:32–39. doi: 10.1016/j.ijpharm.2006.02.049. [PubMed] [Cross Ref]
8. Campos-Aldrete ME, Villafuerte-Robles L. Influence of the viscosity grade and the particle size of HPMC on metronidazole release from matrix tablet. Eur J Pharm Biopharm. 1997;43:173–178. doi: 10.1016/S0939-6411(96)00004-5. [Cross Ref]
9. Miranda A, Millán M, Caraballo I. Study of the critical points of HPMC hydrophilic matrices for controlled drug delivery. Int J Pharm. 2006;311:75–81. doi: 10.1016/j.ijpharm.2005.12.012. [PubMed] [Cross Ref]
10. Miranda A, Millán M, Caraballo I. Study of the critical points in lobenzarit disodium hydrophilic matrices for controlled drug delivery. Chem Pharm Bull (Tokyo) 2006;54:598–602. doi: 10.1248/cpb.54.598. [PubMed] [Cross Ref]
11. Fuertes I, Miranda A, Millian M, Caraballo I. Estimation of percolation thresholds in acyclovir hydrophilic matrix tablets. Eur J Pharm Biopharm. 2006;64:336–342. doi: 10.1016/j.ejpb.2006.05.009. [PubMed] [Cross Ref]
12. Leuenberger H, Rohera BH, Haas C. Percolation theory—a novel approach to solid dosage form design. Int J Pharm. 1987;38:109–115. doi: 10.1016/0378-5173(87)90105-0. [Cross Ref]
13. Caraballo I, Fernandez Arévalo M, Millán M, Rabasco AM, Leuenberger H. Study of percolation thresholds in temary tablets. Int J Pharm. 1996;139:177–186. doi: 10.1016/0378-5173(96)04603-0. [Cross Ref]
14. Stauffer D, Aharony A. Introduction to Percolation Theory. Washington, DC: Francis; 1992.
15. Zallen R. Percolation: a model for all seasons. In: Deutscher G, Zallen R, Adler J, editors. Percolation Structures and Processes. New York NY: The American Institute of Physics; 1983.
16. Ohsugi Y, Nakano T, Ueno K. An immunopharmacological profile of lobenzarit disodium (CCA), a new immunomodulatory anti-rheumatic drug. Int J Immunother. 1985;2:85–92.
17. Castellanos GE, Caraballo I, Bataille B. Tablet design. In: Gad SC, ed.Pharmaceutical Manufacturing Handbook. Hoboken, NJ: John Wiley & Sons; In press.
18. Novoa H, Pellón R, Pomés P, Duque J. Crystal data and x-ray powder diffraction data of lobenzarit acid and lobenzarit disodium. Powder Diffraction. 1996;11:72–74.
19. Ritger PL, Peppas NA. A simple equation for description of solute release. I. Fickian and Non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J Control Release. 1987;5:23–36. doi: 10.1016/0168-3659(87)90034-4. [Cross Ref]
20. Davidson GWR, Peppas NA. Relaxation-controlled transport in P(HEMA-co-MMA) copolymers. J Control Release. 1986;3:243–258. doi: 10.1016/0168-3659(86)90096-9. [Cross Ref]
21. Lin CC, Metters AT. Hydrogels in controlled release formulations: network design and mathematical modelling. Adv Drug Deliv Rev. 2006;58:1379–1408. doi: 10.1016/j.addr.2006.09.004. [PubMed] [Cross Ref]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists